Most Read Articles
Jairia Dela Cruz, 23 Sep 2017
Laparoscopic sleeve gastrectomy (SG) appears to be effective in Asians, with early weight loss correlating with midterm weight maintenance and remission of obesity-related comorbidities 1 year after the surgery, according to a study.
Audrey Abella, 26 Sep 2017
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.
Pearl Toh, 23 Sep 2017
The incidence of cardiovascular (CV) events at 5 years was similar when adding sulphonylureas or pioglitazone to metformin in patients with type 2 diabetes (T2D) inadequately controlled with metformin alone, according to a head-to-head comparison in the TOSCA.IT* trial.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

Surgery, medical programme improve physical behaviour, fitness in T2D patients

22 Dec 2016

In patients with type 2 diabetes (T2D), both Roux-en-Y gastric bypass and the medical programme result in therapeutic lifestyle changes and improved objective and self-reported physical fitness, according to a recent study.

Heart rate, oxygen saturation and perceived impact of weight on health had also improved after surgery, and this could have been caused by greater weight loss.

Researchers assessed the physical behaviour and fitness in participants of the Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D) study, with the purpose of comparing the effects of Roux-en-Y gastric bypass with a multidisciplinary, group-based medical diabetes and weight management programme.

SLIMM-T2D is a randomized, parallel-group trial conducted at a US academic hospital and diabetes clinic with 18- to 24-month follow-up. A total of 38 T2D patients with haemoglobin A1c ≥6.5 percent and body mass index (BMI) 30 to 42 kg/m2 were randomly assigned to either Roux-en-Y gastric bypass or the medical programme.

Researchers conducted a 6-minute walk test to evaluate fitness, self-reported physical activity, standardized physical surveys and cardiometabolic risk assessment at baseline and after intervention.

Improvement in the 6-minute walk test distance was seen in both groups, with greater improvements in oxygen saturation and reduced heart rate after surgery.

At 18 to 24 months after interventions, self-reported physical activity similarly improved, while exercise increased gradually after surgery. However, early substantial increases in the medical group were not fully sustained.

After surgery, self-reported total and physical health were similar by Short Form-36 but improved more in the Impact of Weight on Quality of Life survey. Furthermore, greater improvement was found in cardiovascular risk scores, HbA1c and BMI after surgery.

Further research is warranted to better understand the clinical importance of these improvement with greater weight loss, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 23 Sep 2017
Laparoscopic sleeve gastrectomy (SG) appears to be effective in Asians, with early weight loss correlating with midterm weight maintenance and remission of obesity-related comorbidities 1 year after the surgery, according to a study.
Audrey Abella, 26 Sep 2017
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.
Pearl Toh, 23 Sep 2017
The incidence of cardiovascular (CV) events at 5 years was similar when adding sulphonylureas or pioglitazone to metformin in patients with type 2 diabetes (T2D) inadequately controlled with metformin alone, according to a head-to-head comparison in the TOSCA.IT* trial.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.